Patients were randomly assigned ( @:@ ) via an interactive web-based and voice response system , stratified by number of previous treatment lines and by previous use of bortezomib , to receive @ day cycles of placebo or panobinostat ( @ mg ; on days @ , @ , @ , @ , @ , @ , orally ) , both in combination with bortezomib ( @ mg/m ( @ ) on days @ , @ , @ , @ , intravenously ) and dexamethasone ( @ mg on days @ , @ , @ , @ , @ , @ , @ , @ , orally ) .